Literature DB >> 21855622

The anti-hypertensive effect of Danshen (Salvia miltiorrhiza) and Gegen (Pueraria lobata) formula in rats and its underlying mechanisms of vasorelaxation.

C F Ng1, C M Koon, D W S Cheung, M Y Lam, P C Leung, C B S Lau, K P Fung.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Radix Salviae miltiorrhizae (Danshen) and Radix Puerariae lobatae (Gegen) have long been used in traditional Chinese Medicine and serve as the principal herbs in treating cardiovascular disease. AIMS OF THE STUDY: In the present study, an aqueous extract comprising Danshen and Gegen in the ratio of 7:3 (DG) was investigated for its anti-hypertension in vivo and vasodilative activities ex vivo.
MATERIALS AND METHODS: The anti-hypertensive effect of DG extract was investigated in spontaneously hypertensive rat (SHR) by measuring systolic blood pressure (SBP). Oral administration of DG extract was started at age of 6 weeks and 14 weeks for the preventive and therapeutic studies, respectively. Blood pressure was measured by tail-cuff method biweekly for 12 weeks. The ex vivo vasodilative activities of DG extract, its dependency on endothelium and the involvement of nitric oxide, prostacyclin and potassium channels were investigated using isolated rat aorta ring in organ bath.
RESULTS: For in vivo study, systolic blood pressure was significantly reduced in DG extract-treated groups (90.2 and 300 mg/kg) as compared with the SHR control in both preventive and therapeutic studies. However, DG extract was unable to suppress or delay the onset of hypertension in the preventive study. For ex vivo study, the results showed that DG extract induced a concentration-dependent relaxation in aorta and persisted response was observed with the removal of endothelium. Besides, pretreatment with a non-selective potassium channel inhibitor tetraethylammonium (TEA) also significantly inhibited DG extract-induced vasodilation. Further investigations on specific potassium channel blockers revealed that ATP-sensitive potassium (K(ATP)) channel inhibitor glibenclamide, inward rectifier potassium (Kir) inhibitor barium chloride and voltage-dependent potassium (K(v)) channel inhibitor 4-aminopyridine, but not BK(Ca) channel inhibitor iberiotoxin, exerted significant inhibition on DG extract-induced vasodilation.
CONCLUSIONS: The results of in vivo SHR animal model suggested that DG aqueous extract possessed blood pressure lowering effect on both pre- and post-hypertensive rats, which could be explained by its endothelium-independent vasodilation via the opening of K(ATP), Kir and K(v) channels.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855622     DOI: 10.1016/j.jep.2011.08.006

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  19 in total

Review 1.  Herbs Used for the Treatment of Hypertension and their Mechanism of Action.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  Curr Hypertens Rep       Date:  2017-09-18       Impact factor: 5.369

2.  Inhibitory effects of salviae miltiorrhizae radix (danshen) and puerariae lobatae radix (gegen) in carbachol-induced rat detrusor smooth muscle contractility.

Authors:  Willmann Liang; Ivy Wen Jia Teong; Johnny Chi Man Koon; Clara Bik San Lau; Kwok Pui Fung; Ping Chung Leung
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-02-28

3.  In vitro, ex vivo and in vivo anti-hypertensive activity of Chrysophyllum cainito L. extract.

Authors:  Li-Mei Mao; Xue-Wen Qi; Ji-Heng Hao; Hai-Feng Liu; Qing-Hua Xu; Pei-Li Bu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials.

Authors:  Xingjiang Xiong; Xiaochen Yang; Wei Liu; Bo Feng; Jizheng Ma; Xinliang Du; Pengqian Wang; Fuyong Chu; Jun Li; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-20       Impact factor: 2.629

5.  Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia.

Authors:  Chi-Man Koon; Chun-Hay Ko; Xu-Xu Sun; Sandy Wan-Heng Hoi; Jacqueline Chor-Wing Tam; David Wing-Shing Cheung; King-Fai Cheng; Suet-Yee Pang; Wing-Man Lo; Ping Chook; Clara Bik-San Lau; Wai-Yee Chan; Ping-Chung Leung; Timothy Chi-Yui Kwok; Kwok-Pui Fung
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-23       Impact factor: 2.629

6.  The cardioprotective effect of danshen and gegen decoction on rat hearts and cardiomyocytes with post-ischemia reperfusion injury.

Authors:  Fan Hu; Chi-Man Koon; Judy Yuet-Wa Chan; Kit-Man Lau; Kwok-Pui Fung
Journal:  BMC Complement Altern Med       Date:  2012-12-10       Impact factor: 3.659

7.  Demographic and Prescribing Patterns of Chinese Herbal Products for Individualized Therapy for Ischemic Heart Disease in Taiwan: Population-Based Study.

Authors:  Yu-Chiang Hung; Ying-Jung Tseng; Wen-Long Hu; Hsuan-Ju Chen; Tsai-Chung Li; Pei-Yuan Tsai; Hsin-Ping Chen; Meng-Hsuan Huang; Fang-Yen Su
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

8.  Trends in the treatment of hypertension from the perspective of traditional chinese medicine.

Authors:  Xingjiang Xiong; Xiaochen Yang; Wei Liu; Fuyong Chu; Pengqian Wang; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-26       Impact factor: 2.629

9.  Role of different types of potassium channels in the relaxation of corpus cavernosum induced by resveratrol.

Authors:  Selvinaz Dalaklioglu; G Ozbey
Journal:  Pharmacogn Mag       Date:  2014-01       Impact factor: 1.085

Review 10.  Ten years' research on a cardiovascular tonic: a comprehensive approach-from quality control and mechanisms of action to clinical trial.

Authors:  Ping-Chung Leung; Chi-Man Koon; Clara Bik-San Lau; Ping Chook; William King-Fai Cheng; Kwok-Pui Fung; Timothy Chi-Yui Kwok; Kam-Sang Woo
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.